Understanding Disability in Immune-Mediated CNS Disorders
The study aims to investigate the mechanisms of disability in immune-mediated central nervous system (CNS) disorders through clinical evaluations, MRI, and biological sample collection from patients with such conditions. Healthy volunteers are included as controls.
- Tags
- #MSResearch
- Most relevant to
- —
- Source
- Read original source
Why it matters
This research could lead to improved diagnostic tools and assessments related to neurological disability and disease severity in CNS disorders. Understanding the mechanisms involved may enhance treatment approaches.
What this does not prove
No results are available yet, limiting the ability to draw conclusions about the outcomes. The study primarily serves as a screening protocol without establishing efficacy or effects.
Next milestone
No next milestone was established from the available source.
Study facts
- Study design
- Not reported
- Participants / samples
- Not reported
- Randomised
- Not reported
- Controlled
- Not reported
- Primary endpoint met
- Not reported
- Relevant MS type
- Not reported
- Publication date
- Not reported
- Evidence reviewed
- Trial registry record
- Regulatory approval
- Not reported
- Research areas
- Not classified
Original sources
Supporting passages (3)
subjectsHealthy volunteers (HV) are included as controls for immunological and imaging biomarkers and to obtain normative data for development of new clinical scales and smartphone apps.\n\nDESIGN\n\nCollection of multimodal data (standardized clinical/functional, neuroimaging and molecular/immunological data) during the diagnostic work-up of patients with varied disorders of the CNS in which immune-mediated processes are expected to play a pathophysiological role.\n\nFor the patient cohort, a comprehensive evaluation establishes a definitive diagnosis or confirms diagnosis and subtype of multiple sclerosis (MS) as a pre-requisite for enrollment into NDS clinical trials.
findings"detailedDescription": "OBJECTIVE\n\nThe goal of this study is to define the pathophysiological mechanisms underlying the development of disability in immune-mediated disorders of the central nervous system (CNS) and to distinguish these from beneficial responses of the human immune system to CNS injury.\n\nThe protocol serves as a screening tool for Neuroimmunological Diseases Section (NDS) of the National Institute of Allergy and Infectious Diseases (NIAID) clinical trials and enables development of clinically-useful tools such as diagnostic tests and new, sensitive scales of neurological disability, disease severity and CNS tissue destruction.\n\nThis protocol also serves as a repository to enable prospective institutional review board (IRB) review of research using human samples and data collected under other NDS protocols.\n\nSTUDY POPULATION\n\nPatients with evidence, or suspicion of immune-mediated CNS injury.
limitationsTrial registry record. Publication date: unknown. No results are posted. Planned enrolment and endpoints are not findings.
AI assessment, not yet reviewed by a person · version 1 · Community votes are separate from evidence review.